Research Article

Inflammatory Markers as Prognostic Factors of Survival in Patients Affected by Hepatocellular Carcinoma Undergoing Transarterial Chemoembolization

Table 3

Pretreatment factors affecting overall survival.

nmOSUnivariate Hazard ratio (95% CI)Multivariate

SexMale39460.1285
Female1023

Age (years)>7625490.03250.4838 (0.1267–1.8480)0.2908
<762423

EtiologyHCV18240.9782
Cripto1946
Alcol10
Others228

Child-Pugh class517480.03650.9823 (0.1690–5.7078)0.9842
62133
7717
8314
9123

NLR>2.0325180.042911.5283 (2.3361–56.8918)0.0028
<2.032433

PLR>87.9925240.9737
<87.992433

BCLC stageB34480.01991.8542 (0.4128–8.3281)0.4229
C1523

Tumor size (cm)>526240.6515
<52333

Number of tumors<325240.2565
3–5917
>51546

Extrahepatic spreadAbsent4928
Present0

Bilobar spreadAbsent18460.6596
Present3124

AscitesAbsent37480.0964
Present1223

Albumin>3.7250.1210
<3.72422

Bilirubin>0.8425230.2664
<0.842433

INR>1.1825220.021816.9893 (1.6017–180.2098)0.0193
<1.1824

Creatinine>0.7825240.7856
<0.782424

GFR>94.525210.7606
<94.52424

BCLC = Barcelona Clinic Liver Cancer; Cripto = criptogenetic; GFR = glomerular filtration rate; HCV = hepatitis C virus; INR = International Normalized Ratio; mOS = median overall survival; NLR = neutrophil to lymphocyte ratio; PLR = platelet to lymphocyte ratio.